Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Re: Prior reexam matures to certificate while later reexamination >>eggbert

<So one can only expect another reexamination in the future with respect to the new 336 claims 11-20. Those new claims have not come under the scrutiny of a reexamination.>

I have not yet looked, but typically these claims all contain the basic features of prior claims and then add a new feature. Corrections welcomed. Point being there may be requests, but if the prior art can't get past the basic features, then the USPTO is not going to waste their time. Requester would need to find some prior art which is not already of record that manages to first overcome all those basic features. IMHO

<With the current reexamination, time will tell if TPL deems it necessary to amend claims 1-10. They have until the second week of January to do so unless they file for extension. >

Why on earth would we try to amend anything w/o knowing for sure if an office action rejection is to follow and what is in it?

GLTA, Opty

Share
New Message
Please login to post a reply